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Over the last decade it has become clear that the im-
munological response and clinical course in sepsis
patients is too complex to simply regard it as ‘hyperin-
flammation-induced organ failure’. In contrast to the
previous belief that patients mainly suffer from an ex-
aggerated pro-inflammatory response, it has now be-
come evident that a pro- and anti-inflammatory
response are mounted simultaneously [1, 2]. Whether
pro-inflammation or anti-inflammation is the overrul-
ing immune response may differ between patients and
evolve over time in an individual patient [2], and this
may explain why all previous clinical studies in sepsis
patients using interventions to attenuate the immune
response are negative [3]. Greater appreciation for the
role of the dysregulated immune response is repre-
sented in the new definition of sepsis [4], defining sep-
sis as a life-threatening organ dysfunction caused by a
dysregulated host response to infection.
One size does not fit all
Dozens of trials have convincingly demonstrated that in-
hibition of the immune response exerts no overall bene-
ficial effects in the heterogeneous group of sepsis
patients. Nevertheless, it is conceivable that a subgroup
of patients may have benefited from inhibition of the im-
mune response, but that in another subgroup of patients
where immune suppression was the overriding immune
dysregulation, no beneficial (or even detrimental) effects
were evoked. Indeed, the interleukin (IL)-1 receptor
blockade phase 3 trial published in 1997 [5] showed no
effect of immune suppression with anakinra on mortality
in patients suffering from severe sepsis. Based on new
insights, a post-hoc analysis of this study performed
19 years later [6] identified that 5.6% of the study popu-
lation presented with features of macrophage activation
syndrome (sepsis with concurrent hepatobiliary dysfunc-
tion/disseminated intravascular coagulation). In this sub-
group, mortality was 65% in the placebo-treated patients
and 35% in the IL-1 receptor blockade patients (p =
0.0006) [6]. Naturally, this is a post-hoc analysis and no
definitive conclusions can be drawn, but it does suggest
that a specific subgroup of ‘hyperinflamed’ sepsis pa-
tients might benefit from inhibition of the immune re-
sponse. The extent of this effect warrants further
prospective study.
In contrast to this subgroup of patients that are hyper-
inflamed, observational data indicate that in a large pro-
portion of sepsis patients immune suppression is the
overriding immune dysregulation. For instance, sepsis
patients are more likely develop infections with oppor-
tunistic bacteria or fungi [7] and up to 40% of patients
show positive viral polymerase chain reactions (PCRs)
indicating reactivation of latent viruses [8]. Furthermore,
in a post-mortem study [9], profound suppression of im-
mune cell function was found in tissue from patients
that died of sepsis. Theoretically, pharmacological inter-
ventions aimed to stimulate recovery of this immune
suppression might benefit this subgroup of patients.
Based on the above, it is clear that differentiation
within sepsis patients is required to move this field for-
ward, and immune phenotyping of sepsis patients may
pave the way towards a more personalized approach,
also called ‘precision medicine’.
* Correspondence: peter.pickkers@radboudumc.nl
1Department of Intensive Care Medicine, Radboud Institute for Molecular Life
Sciences, Radboud University Medical Center, Internal mail 710, P.O. Box
9101, Nijmegen 6500 HB, The Netherlands
2Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pickkers and Kox Critical Care  (2017) 21:11 
DOI 10.1186/s13054-016-1583-z
Determining the immune status of sepsis patients
Various ways to gauge the immune status of sepsis pa-
tients have been described [2], and many more will
likely emerge in the following years as a consequence
of progress in our insight of which pathways play a role
in the development of immune suppression in sepsis
patients. For example, recent evidence points towards
an important role for defects in energy metabolism in
the impaired function of immune cells of septic pa-
tients [10]. As such, it can be envisioned that profiling
of cellular metabolism provides a snapshot of the
current immunological state of a septic patient and
may be used to guide treatment. Furthermore, the pro-
grammed death 1 (PD-1) pathway appears to be of
particular relevance in sepsis-induced immune suppres-
sion, and expression of PD-L1 (the ligand for PD-1) on
the cell surface of monocytes is associated with risk
stratification and mortality in septic patients [11]. As ex
vivo addition of antibodies against PD-1 or PD-L1 re-
stored function of monocytes, neutrophils, T cells, and
natural killer (NK) cells [12], the data from clinical
studies in the field of oncology that show that treat-
ment with anti-PD-1/PD-L1 antibodies is feasible and
safe [13] is of interest to the sepsis field. When these
compounds are tested in immune suppressed sepsis pa-
tients, patient group enrichment by determination of
monocyte PD-L1 expression is clearly of utmost rele-
vance. Several other compounds (including interferon
(IFN)γ, granulocyte macrophage colony-stimulating fac-
tor (GM-CSF), and IL-7) that stimulate the immune
system through various pathways have already shown
promising results in preclinical studies, and some even
in small patient studies. For a fair chance of clinical
success, it is pivotal that we do not make the same mis-
take again by advocating the use of these compounds in
all sepsis patients, but rather use them in an immune-
suppressed subgroup.
Up to now, two assays to determine the immune sta-
tus in sepsis patients have been studied most exten-
sively: ex vivo lipopolysaccharide (LPS)-induced
cytokine production by leukocytes, and monocytic hu-
man leukocyte antigen-D related (HLA-DR) expression.
The LPS-stimulated whole blood functional assay pro-
vides insight in the actual cell function, while determin-
ation of monocyte HLA-DR expression is more specific
and at the single cell level. Drewry et al. recently com-
pared these two methods head-to-head [14]. In 83 pa-
tients, of which over 60% suffered from septic shock,
more than a quarter of the patients developed a sec-
ondary infection and in total 30% died. Blood samples
were collected at three time points (days 1–2, days 3–4,
and days 6–8 after sepsis diagnosis) and results were
related to the development of secondary infections and
mortality. Their main finding is that monocytic HLA-
DR expression is a more accurate predictor for second-
ary infections and mortality than ex vivo LPS-induced
cytokine production, and in their paper they describe
several explanations for their finding. The authors did
not calculate specificity and sensitivity, as a specific
threshold would have to be chosen to designate the test
as being “positive” or “negative”. Other researchers [15]
have used values <8000 antibodies/cell as the diagnostic
threshold for immunosuppression to investigate the ef-
fect of immunostimulatory therapy. Also, although it is
tempting to speculate that the change in HLA-DR ex-
pression results in an increased risk to develop second-
ary infections and is directly related to the impaired
outcome in these patients, the authors wisely refrain
from such an interpretation as it could also be an epi-
phenomenon: more severely ill patients might be more
likely to develop a secondary infection and have a
higher mortality independent of HLA-DR expression.
Of interest, the change in HLA-DR expression that was
most associated with the development of secondary in-
fections occurred between days 1–2 to days 3–4 (me-
dian change in HLA-DR of −934 antibodies/cell; p =
0.054). As the median time to onset of secondary infec-
tion was 9.4 (interquartile range (IQR) 5.5 to 10.0) days,
this indicates that the change in HLA-DR expression
preceded the diagnosis of the secondary infection. It
appears likely that HLA-DR expression may even be
lower in the days immediately preceding the develop-
ment of a secondary infection, but because of the lim-
ited number of patients evaluated in each group, the
current study was underpowered to detect this. Ultim-
ately, it may be more informative to assess multiple im-
munological markers concurrently or monitor changes
in markers over time.
In conclusion, it is important to emphasize that the
aim of the present study was not to investigate cause-
effect relationships, as it remains unclear if a decrease in
HLA-DR expression is a true predictor or merely an epi-
phenomenon. Nevertheless, it shows that HLA-DR ex-
pression is more accurate in predicting secondary
infections and death in sepsis patients than LPS-induced
cytokine production. This indicates that HLA-DR ex-
pression may be used to identify whether or not a sepsis
patient is in the immunosuppressive phase of their dis-
ease. This is of utmost importance, as it has become
clear that undifferentiated immunomodulatory therapy
in sepsis patients is bound to fail. It appears plausible
that some patients may benefit from inhibition of the
immune response, while others may benefit from stimu-
lation of the immune response. Immunostimulatory
treatment should only be offered to those patients who
suffer from a suppressed immune system and, for now,
monocytic HLA-DR expression is the optimal marker to
determine this.
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